We’re constantly striving for innovation to ensure we deliver your trial as efficiently as possible. Over the last 28 years, Kendle has conducted more than 600 Phase IIIB-IV studies, involving more than 1.5 million patients so we know what works and what doesn’t.
When appropriate, we’ll use remote monitoring to track the progress of your sites and exercise our ingenuity and creativity in study design to help you exceed the local regulatory requirements and achieve your commercial objectives. Our keen understanding of cultural norms also enables us to help you meet the retention challenges of long-term studies.